Clinical Pharmacology Analytical Core

临床药理学分析核心

• 批准号: 8321645
• 负责人: David R. Jones
• 金额: $ 4.59万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8321645
• 关键词: African American; Animals; Antineoplastic Agents; Aromatase Inhibitors; Arts; Back; Basic Science; Biological Assay; CYP2D6 gene; CYP3A4 gene; Cancer Center; Cancer Center Support Grant; Cancer Control Research; Caucasians; Caucasoid Race; Cell Culture Techniques; Cell Extracts; Charge; Child; Children' s Oncology Group; Clinic; Clinical; Clinical Pharmacology; Collaborations; Cultured Cells; Data; Development; Developmental Therapeutics Program; Disease-Free Survival; Dose; Drug Exposure; Drug Interactions; Drug Kinetics; Ensure; Enzymes; Equipment; Excretory function; Exemestane; Fluoxetine; Funding; Genetic Polymorphism; Germany; Goals; Grant; Head; High Pressure Liquid Chromatography; Home environment; Hospitals; Hot flushes; Housing; Human; In Vitro; Indiana; Individual; Italy; Korea; Label; Laboratories; Laboratory Research; Lead; Letrozole; Light; Maintenance; Malignant Childhood Neoplasm; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Medicine; Mentored Patient-Oriented Research Career Development Award; Metabolism; National Institute of General Medical Sciences; Nitrogen; North Central Cancer Treatment Group; Outcome; PTK787; Paclitaxel; Paroxetine; Patient Care; Patients; Pediatric Oncologist; Pharmaceutical Preparations; Pharmacogenetics; Pharmacogenomics; Pharmacology and Toxicology; Phase; Phase III Clinical Trials; Plasma; Policies; Preparation; Protocols documentation; Publications; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Retrospective Studies; Saint Jude Children' s Research Hospital; Sampling; Scheme; Services; Site; Spain; Structure; System; Tamoxifen; Technology; Time; Tissue Extracts; Toxic effect; Translations; United States National Institutes of Health; Universities; Variant; Vincristine; Woman; Work; absorption; base; cancer therapy; cost; design; dosage; genetic variant; high risk; in vivo; inhibitor/antagonist; instrumentation; malignant breast neoplasm; member; microbial alkaline proteinase inhibitor; operation; programs; research study; response; small molecule; square foot; success; trial comparing; tumor

The Clinical Pharmacology Analytical Core (CPAC) assists Indiana University Simon Cancer Center (IUSCC) investigators in support of research projects and scientific goals, CPAC has been in existence since September 2004 and is the only laboratory on campus that provides investigators state-of-the-art technology to quantify small molecules, drugs, and metabolites, to identify compounds based on their mass spectra, and to analyze pharmacokinetic data. Access to state-of-the-art instrumentation for quantification of drugs and metabolites is an invaluable resource for all cancer investigators in the IUSCC. The CPAC develops and performs assays to identify and/or quantify drugs and metabolites from in vitro (including tissue extracts, cell culture and cell extracts) and in vivo studies (including humans or other animals). It also conducts pharmacokinetic analyses that describe drug (or metabolite) concentrations in the body over a period of time, from absorption to excretion, and information on drug exposure. These services ultimately assist investigators in the analysis of their research protocols regarding pharmacokinetics, pharamacodynamics, pharmacogenetics, toxicity, tumor response and identification of appropriate individualized therapies. This technology has allowed IUSCC investigators to make critical pharmacogenetic observations that are already impacting patient care.

临床药理学分析核心 (CPAC) 协助印第安纳大学西蒙癌症中心 (IUSCC) 为了支持研究项目和科学目标，CPAC 自成立以来一直存在 2004 年 9 月，是校园内唯一为研究人员提供最先进技术的实验室 量化小分子、药物和代谢物，根据质谱识别化合物，以及 分析药代动力学数据。获得最先进的药物定量仪器和 对于 IUSCC 的所有癌症研究人员来说，代谢物是宝贵的资源。 CPAC 开发并执行分析方法来识别和/或量化体外药物和代谢物 （包括组织提取物、细胞培养物和细胞提取物）和体内研究（包括人类或其他 动物）。它还进行药代动力学分析，描述药物（或代谢物）浓度 一段时间内身体从吸收到排泄的信息，以及药物暴露的信息。这些服务 最终协助研究人员分析其有关药代动力学的研究方案， 药效学、药物遗传学、毒性、肿瘤反应和适当的鉴定 个体化治疗。这项技术使 IUSCC 研究人员能够做出关键的药物遗传学研究 已经影响患者护理的观察结果。